



Curriculum Vitae

Personal information

Edo Richard

Work experience

1. Employer: Radboud university medical centre
 - Start date: 092014
 - End date:
 - Position: Prof. of Neurology
 - Activities: clinical neurology (patient care), scientific research, teaching
 - Country: Netherlands
2. Employer: Academic Medical Centre
 - Start date: 012011
 - End date: 082014
 - Position: neurologist
 - Activities: scientific research
 - Country: Netherlands
3. Employer: Academic Medical Centre
 - Start date: 012021
 - End date:
 - Position: Professor of Neurology, 0,2 FTE
 - Activities: researching the vascular component of dementia from a population perspective
 - Country: Netherlands

Education and training

1. Subject: Academic Medical Centre, University of Amsterdam
 - Start date: 1995
 - End date: 2001
 - Qualification: MD
 - Organisation: MD
 - Country: Netherlands
2. Subject: Academic Medical Centre, University of Amsterdam
 - Start date: 2003
 - End date: 2010
 - Qualification: Neurologist
 - Organisation: clinical neurologist, PhD (vascular factors in dementia _ prevention and pathology)
 - Country: Netherlands

Additional information

Publications

1. Rico V,**Richard E**, ...Sankary L. Recommending approaches to sharing individual research results in Alzheimer's Disease research: A multidisciplinary expert Delphi consensus. *J Alz Dis* 2025;25 Sept online ahead of print
2. Van Apeldoorn J, Jansen J,**Richard E**, Moll van Charante EP. First-generation Turkish Immigrants' Views and Preferences on Cardiovascular Disease Prevention in Primary Care - a Qualitative Study in the Netherlands. *Migration and Health* – accepted for publication
3. Lindhout J, Hoevenaer-Blom MP, van Dalen JW, Song M, Dong L, Wang W, **Richard E**, Moll van Charante EP, van Middelaar T. Association between hypertension and dementia risk in Low- and Middle-Income Countries: A systematic review. *The Journal of Aging Research and Lifestyle* 2025 – accepted for publication

4. Brooks R, Hoevenaar-Blom MP, Coley N, Moll van Charante EP, Barnes L, **Richard E***, Brayne C* (*shared last author). The smartphone barrier: uncovering the digital divide in mHealth prevention among disadvantaged middle- and older-aged UK communities. *BMJ digital health and AI 2025 – accepted for publication*
5. Rasing A, Hilkens N, **Richard E**, de leeuw FE. Young stroke. *Tijdschr Neurol Neurochir 2025. In Dutch – accepted for publication*
6. Endt vd AR, Lindhout JE,**Richard E**,Moll van Charante EP. A coach-supported mHealth lifestyle intervention to reduce dementia risk in persons with low SES or a migration background -a qualitative co-design study. *J Participatory Med 2025 – accepted for publication*
7. Van Gool WA, Siebrand F, Larson E, Brayne C, **Richard E**. Evidence gap in blood biomarkers for Alzheimer’s Disease. *BMJ 2025; Aug 5;390:e084781*
8. Graafland C,**Richard E**,Bunnik E. Ethics of disclosure of onset-predicting biomarker test results for genetic frontotemporal dementia in the research context. *Alz & Dem DADM 2025. Jun 11;17(2):e70133*
9. Lindhout J, van Dalen JW, van Gool WA, **Richard E**, Hoevenaar-Blom MP. The association of apathy with incident dementia: a multiple mediation analysis of cardiovascular risk factors. *Int J Ger Psych 2025 – accepted for publication*
10. Graafland C, Seelaar H, Donker Kaat L, Panman JL, Jiskoot LC, Kleefstra T, Poos JM, **Richard E**, Schermer M, van Swieten J, Bunnik E. “It seems enormously valuable to me.” Perspectives of (potential) carriers of genetic FTD on onset-predictive biomarker testing. *Alz Res Ther 2025 – accepted for publication*
11. Van der Molen L, Boenink M, van Lente H, **Richard E**. Changing definitions of disease: Transformations in the diagnostic criteria for Alzheimer’s Disease. *Alz & Dem 2025 – online first 13-04-2025*
12. Van der Slot AJC, Mooijaart SP, van Dalen JW, Hoevenaar-Blom MP, **Richard E**, Giltay E. How depressive symptoms, apathy, daily activities and cognitive decline are dynamically connected in older people: a network analysis. *Am J Ger Psych 2025 – accepted for publication*
13. Oomens JE,**Richard E**,Visser PJ. Identifying pathways tot he prevention of dementia: The Netherlands Consortium of Dementia Cohorts. *BMC Neurology 2025; 25(1):59.DOI 10.1186/s12883-024-03995-4*
14. Hafdi M, Taylor-Rowan M, Drozdowska B, Elliot E, McGuire L, **Richard E**, Quinn T. Prediction of dementia using CT imaging in stroke (PRODUCTS). *Eur Stroke Journal 2025 -accepted for publication*
15. Palsma T, de Heus R, **Richard E**, Claassen J. Day-to-day blood pressure variability in older persons - optimising measurement. *J Hypertension 2025 – accepted for publication*

16. Van Steenhoven R, **Richard E**. Revisie richtlijn dementie. *Tijdschr. Neurol. Neurochir 2025 (Dutch) – accepted for publication*
17. Endt v.d. AR, Hoevenaar-Blom MP,Moll van Charante EP, **Richard E**. mHealth Intervention for Dementia Prevention through lifestyle Optimisation (MIND-PRO) in a primary care setting: protocol for a randomized controlled trial in people with low SES and/or migration background *BMJ Open 2025; Feb 3;15(2):e088324. doi: 10.1136/bmjopen-2024-088324*
18. Hoevenaar-Blom MP, Shourik J, van Dalen JW, van Gool WA, Andrieu S, **Richard E**, Coley NC, Moll van Charante EP. Mediation of dementia risk factors in the effect of two large multidomain interventions on dementia incidence. *Alz & Dem 2025 – accepted for publication*
19. Lindhout J, Endt vd AR, Hoevenaar-Blom MP, van Dalen JW, Deckers K, Geerlings M, Galenkamp H, **Richard E**, Moll van Charante EP. Midlife dementia risk scores in a multi-ethnic population in the Netherlands: the HELIUS study. *J Public Health 2025 – accepted for publication*
20. Coley N, Hoevenaar-Blom MP,**Richard E***, Andrieu S* (equal contribution). Searching for responders to multidomain dementia prevention in late-life: a pooled analysis of individual participant data from the MAPT and preDIVA trials. *Alz & Dem 2024 – accepted for publication*
21. Van Apeldoorn J, Jansen L, Hoevenaar-Blom M, Harskamp RE, Galekamp H, van den Born BJ, Agyemang C, **Richard E**, Moll van Charante EP. Antihypertensive medication category prescriptions and blood pressure control in African Surinamese and Ghanaian migrants with hypertension in Amsterdam, the Netherlands: the HELIUS study. *High Blood Pressure & Cardiovascular Prevention - accepted for publication*
22. Milne R, **Richard E**, Brayne C. Challenges associated with the development of trial ready cohorts. *BMJ 2025 jan 7; 388:e080275*
23. Van Apeldoorn J, Hageman HJ, Harskamp RE, Agyemang C, van den Born BJ, van Dalen JW, Galekamp H, Hoevenaar-Blom MP, **Richard E**, van Valkengoed IG, Visseren FL, Dorresteyn Ja, Moll van Charante EP. Adding ethnicity to cardiovascular risk prediction: external validation and model updating of SCORE2 using data from the HELIUS population cohort. *Int J Cardiol 2024 - accepted for publication*
24. Ronner D, Oostra D, Claassen, **Richard E**, Perry M. Diagnostic Information in GP referral letters to memory clinics: a cohort study. *British Journal of General Practice Open 2024 – Accepted for publication*
25. Walsh S, Merrick R, Milne R, Nurock S, **Richard E**, Brayne C. Considering challenges for the new Alzheimer's drugs: Clinical, population and health system perspectives. *Alz & Dem 2024;20(9):6639-46*
26. Van Dalen JW, Schroevers J, **Richard E**, Hoevenaar-Blom MP, van den Born BJ, van Gool WA, Moll van Charante EP. Adverse lipid profiles are associated with lower dementia risk in older people. *JAMDA 2024 – Online first June 2024*

27. Zonneveld T, ...**Richard E**... Kruyt ND. Active blood pressure reduction versus no blood pressure reduction in acute ischaemic stroke patients with blood pressure levels exceeding guideline-recommended thresholds for intravenous thrombolysis: A prospective, observational, cluster-base, parallel-group study. *The Lancet – Neurology – online first 17-05-2024*
28. Schroevers J, Eggink E, van Middelaar T,.....**Richard E**, van Dalen JW, Moll van Charante EP. Antihypertensive Medication class effects and the risk of dementia – a primary care database study. *Lancet Regional Health – Europe 2024; May 15;42:100927*
29. Moll van Charante EP*, Hoevenaar-Blom MP*, Song M, Andrieu S, Barnes L, Birck C, Brooks R, Coley N, Eggink E, Georges J, Hafdi M, van Gool WA, Handels R, Hou H, Lyu J, Niu Y, Song L, Wang W, Wang Y, Wimo A, Yu Y, Zhang J, Zhang W, Brayne C*, Wang W*, **Richard E***. Prevention of Dementia using Mobile Phone applications - a multinational randomized controlled clinical trial. *Lancet Healthy Longevity 2024 Jun;5(6):e431-e442*
30. Lindhout J, **Richard E**, Hafdi M, Perry M, Moll van Charante EP, van Gool WA. The association of ancillary diagnostic tests with outcome in dementia. *JAMDA 2024 – online first June 2024*
31. Visser AE, de Vries NM, **Richard E**, Bloem B. Tackling vascular risk factors: a possible disease modifying intervention in Parkinson’s disease. *NPJ Parkinson Disease 2024 – online first*
32. Jansen E, Hilkens N, van Dalen JW, Cai M, Jacob M, Marques J, Norris DG, Duering M, **Richard E**, Tuladhar A, de Leeuw FE. Visit to visit blood pressure variability is associated with progression of cerebral small vessel disease over 14 years. *Blood Pressure 2024 – accepted for publication*
33. Hilkens N, de Leeuw FE, Klijn CJ, **Richard E**. Blood pressure variability and progression of White matter hyperintensities after stroke. *Cerebr Circ Cogn 2024 – accepted for publication*
34. Liu K, Walsh S, Brayne C, Merrick R, **Richard E**, Howard R. How should we evaluate clinical benefits in Alzheimer’s Disease? *Lancet Healthy Longevity 2024;4(11):e645-51*
35. Den Brok M*, van Dalen JW*, Hilkens N, Klijn K, Marcum Z, van gool WA, Crane P, Larson E, **Richard E**. Very long-term Blood pressure variability and the risk of dementia. *JAMA Network Open 2023 Oct 2;6(10) e2340249*
36. Voorend CGN....**Richard E**,Mooijaart S. Prevalence of apathy and association with physical impairment, cognitive decline and mortality in older chronic kidney disease patients; a prospective cohort study. *AJKD 2023 - accepted for publication*
37. Aovare P,**Richard E**,Agyemang C. Effectiveness of Mobile Health Interventions (mHealth) in Diabetes and Hypertension Management in Africa - A systematic review and meta-analysis. *JMIR - mHealth and uHealth 2023.*

accepted for publication

38. M.J. Oosterwegel; J.H. Krijthe, M.G.H.E. den Brok, L. van den Heuvel, **E. Richard**, T. Heskes, B.R. Bloem, L.J.W. Evers. The effect of cardiovascular risk on disease progression in de novo Parkinson's disease patients: an observational analysis. *Frontiers in Neurology 2023 – accepted for publication*
39. Van Apeldoorn J.A.N., Roozkrans AR, Harskamp R, **Richard E**, Agyemang C, Moll van Charante EP. General practitioners' views on cardiovascular risk management for ethnic minorities – a qualitative study in the Netherlands. *Family practice 2023 – accepted for publication*
40. Daphne M.P. Naessens, Judith de Vos, **Edo Richard**, Micha M.M. Wilhelmus, Cornelis A.M. Jongenelen, Edwin R. Scholl, Nicole N. van der Wel, Johannes A. Heijst, Charlotte E. Teunissen, Gustav J. Strijkers, Bram F. Coolen, Ed VanBavel, Erik N.T.P. Bakker. Effect of long-term antihypertensive treatment on cerebrovascular structure and function in spontaneously hypertensive rats. *Sci Rep 2023 – accepted for publication*
41. Lindhout J, van Dalen JW, van Gool WA, **Richard E**. Quasi-experimental study designs for dementia prevention. *Alz & Dem 2023;19(8):3722-30*
42. Claassen J, Mooijaart S, **Richard E**, Moll van Charante EP. Which Target value for blood pressure in frail older persons? *Ned Tijdschr Geneesk 2023;March 15;167:D7334 (article in Dutch)*
43. Walsh S, Govia I, Peters R, **Richard E**, Stephen B, Wilson NA, Anstey K, Brayne C. What would a population-level approach to dementia risk reduction look like, and how would it work? *Alz & Dem 2023 (Jul);19(7):3203-3209*
44. Walsh S, Merrick R, **Richard E**, Nurock S, Brayne C. Lecanemab for Alzheimer's Disease. *BMJ 2022. Online first 19-12-2022*
45. **Richard E**, Bloem B. Monoclonal antibodies in neurodegenerative disease may work, but they don't help. *J Park Dis 2022 – online first*
46. Zhang J*, Eggink E*, Zhang X, Li X, Jiang B, Liu H, Ge S, Zhang W, Lyu J, Niu Y, Yu Y, Hou H, Xu X, Ye X, Wang W, Terlou R, **Richard E**, Wang W, Wang Y, Moll van Charante EP, Song M. Needs and views on healthy lifestyles for the prevention of dementia through mobile health (mHealth) interventions in China: a qualitative study. *BMJ Open 2022 – accepted for publication*
47. Schroevers J, Eggink E, Hoevenaar-Blom M, van Dalen JW, van Middelaar T, van Gool WA, **Richard E**, Moll van Charante EP. Antihypertensive medication classes and the risk of dementia over a decade of follow-up. *J Hypert 2023;41(2):262-70*
48. Hafdi M, Mutsaerts HJ, Petr J, **Richard E**, van Dalen JW. Atherosclerotic risk is associated with cerebral perfusion. *Neuroimage Clinical 2022;36:103142*
49. Markus H,**Richard E**, ...Dichgans M. Framework for clinical trials in cerebral small vessel disease (FINESSE) – a review. *JAMA Neurology 2022 – online first 15 August 2022*

50. Eggink E*, den Brok M,* Hoevenaar-Blom MH, Moll van Charante EP, van Gool WA, **Richard E**, van Dalen JW. Low Values for Blood Pressure, BMI, and Non-HDL Cholesterol and the Risk of Late-Life Dementia. *Neurology* 2022;90(15): e1630-39
51. Abdulrahman H, van Dalen JW, Moll van Charante EP, van Gool WA, **Richard E**. Hypertension and Alzheimer pathology at autopsy – a systematic review. *Alz & Dem* 2022;18(11):2308-26
52. Yassine HN, ...,**Richard E**,Schneider L. Nutrition State of Science and Dementia Prevention: Recommendations of the Nutrition for Dementia Prevention Working Group. *Lancet healthy Longevity* 2022;3(7):e501-e512
53. Janssen Daalen J, Schootmeijer S, **Richard E**, Darweesh, S, Bloem B. Towards prevention of Parkinson's Disease – lifestyle interventions. *Neurology* 2022;99(7 suppl 1):42-51
54. Creavin ST, Noel Storr AH, Langdon RJ, **Richard E**, Creavin AL, Cullum S, Purdy S, Ben Schlomo Y. Clinical judgement by primary care physicians for the diagnosis of all-cause dementia or cognitive impairment in symptomatic people. *Cochrane database of syst reviews* 2022- online first 17 June
55. Bunnik EM, Smedinga M, Milne RM, George J, **Richard E**, Schermer M. Ethical frameworks for disclosure of Alzheimer's disease biomarkers to research participants: How to resolve conflicting norms? – *Ethics & Human Research* 2022 – accepted for publication
56. Whitehouse P,**Richard E**, Schneider, L. Call for accelerated withdrawal of aducanumab. *J Alz Dis* 2022;87(3):1003-1007
57. Andre L, Coley N,**Richard E**,Andrieu S. mHealth for the prevention of dementia and CVD – a systematic review. *Clinical Interventions in Ageing* 2022;17:1599-1624
58. Abdulrahman, Smedinga M, ...Verbeek M, **Richard E**, Perry M. The role of biomarkers for CAA – a qualitative study among clinicians. *J Alz dis* 2022;87(2):807-16
59. Abdulrahman H, Hafdi M, Mutsaerts HJ, Petr J, van Gool WA, **Richard E**, van Dalen JW. Cerebral perfusion and the risk for cognitive decline and dementia in community-dwelling older persons. *Cerebral circulation – cognition and behaviour* 2022; feb 20(3):100-125
60. Eggink E, Hoevenaar-Blom MH, ...**Richard E**, Moll van Charante EP. Attitudes and views on healthy lifestyle interventions for the prevention of dementia and cardiovascular disease among older people with low socioeconomic status: a qualitative study. *BMJ Open* 2022;12(2):e055984
61. Moll van Charante EP, **Richard E**, Perry M. Memory problems – Teaching article (Dutch). *Nederlands Tijdschr Geneesk* 2022 – accepted for publication
62. Coley N, Andre L, Hoevenaar-Blom MH, Ngandu T, Beishuizen C, Barbera M, van Wanrooij LL, Kivipelto M, Soininen H, Brayne C, van Gool WA, Moll Van

- Charante EP, **Richard E**, Andrieu S, for the HATICE and PRODEMOS study groups. Engagement of older adults with a preventive digital health intervention: predictive factors and associations with cardiovascular and dementia risk. *JMIR* 2022;24(5):e32006
63. Eggink E, Hafdi M, Hoevenaar-Blom MH, Witvliet MP, Andrieu S, Barnes L, Brayne C, Brooks R, Coley N, Georges J, van der Groep A, van Marwijk H, van der Meijden M, Song L, Song M, Wang Y, Wang W, Wang W, Wimo A, Ye X, Moll van Charante EP, **Richard E**. Design and development of a mobile health platform for dementia prevention in the Prevention of Dementia using mobile phone applications (PRODEMOS) project. *Frontiers in Neurology* 2021;12:733878
64. Walsh S, Govia I, Wallace L, **Richard E**, Peters R, Anstey K, Brayne C. A whole population approach is required for dementia risk reduction. *Lancet Healthy Longevity* 2022;3(1):e6-e8
65. Hafdi M, Hoevenaar-Blom MH, **Richard E**. Multimodal interventions to prevent dementia. *Cochrane database of systematic reviews* 2022;11(11): CD013572
66. Van Dalen JW, Brayne C, Crane P, fratiglioni L, Larson EB , Lobo A, Lobo E, Marcum Z, Moll van Charante EP, Qiu C, Riedel-Heller, Roehr S, Ryden L, Skoog I, van Gool WA, **Richard E**. Systolic blood pressure and the risk of dementia – impact of age, U-shapes and the competing risk of mortality. *JAMA Int Med* 2022;182(2):142-52
67. Abdulrahman H, **Richard E**, Moll van Charante EP, van Gool WA, van Dalen JW. Sex differences in the association between subjective cognitive complaints and the risk of dementia. *J Alz Dis* 2021;85(1):283-94
68. Quinn TJ; **Richard E**; O'Brien J; Forchhammer B; Teuschl Y; Gillebert C; Bruffaerts R; Verdelho A; Schmidt R; Gattringer T; Pendlebury S; Merriman N; Ghaziani E; Mijajlovic M; Ball E; Hafdi M; Drozdowska B; Markus HS. European Stroke Organisation (ESO) and European Academy Neurology (EAN) Joint Guidelines on Post Stroke Cognitive Impairment. *Eur J Neurology* 2021;28(12):3883-3920
69. Abdulrahman H, Jansen E, Hoevenaar-Blom M, van Bussel E, van Wanrooij L, van Dalen JW, van Gool WA, **Richard E**, Moll van Charante EP. Diagnostic accuracy of the Telephone Interview for Cognitive Status (TICS) for the detection of dementia in primary care. *Ann Fam Med* 2022;20(2):130-36
70. Hoevenaar-Blom MH, **Richard E**, Moll van Charante EP, van Wanrooij LL, van Dalen JW, van Gool WA. preDIVA extended follow-up. *JAMA Neurology* 2021;78(12):1527-28
71. Lammers N, Van Wanrooij L, van Dalen JW, Schmand B, van Gool WA, Nederkoorn PJ, **Richard E**. The course of post-stroke apathy in relation to cognitive functioning: a prospective longitudinal cohort study. *Aging, Neuropsychology and Cognition* 2021 – online first 8 Sept 2021
72. **Richard E**. Selecting the target population for new Alzheimer drugs – challenges and expectations. *J Med Ethics* 2021;47(9):615-16

73. Smedinga M, Bunnik E, **Richard E**, Schermer M. Should doctors offer biomarker testing to those afraid to develop Alzheimer's dementia? – Applying the method of reflective equilibrium for diagnostic dilemmas. *Journal of Bioethical Inquiry* 2022;19(2):287-97
74. Den Brok M, Hoevenaar-Blom MH,**Richard E**. HATICE IPD on cognitive outcomes and depression. *J Prev of Alz Dem* 2022;9(1):96-103
75. Tromp K, Bunnik E, Smedinga M, **Richard E**, Schermer M. Early detection of AD biomarkers and the ethical criteria for screening programs. *Am. J Bioethics Neuroscience* 2021;12(4):231-33
76. Eggink E, Hafdi M, Hoevenaar-Blom M, Song M, Andrieu S, Barnes L, Birck C, Brooks R, Coley C, Ford E, Georges J, van der Groep A, van Gool WA, Handels R, Hou H, Li D, Liu H, Lyu J, van Marwijk H, van der Meijden M, Niu Y, Sadhwani S, Song L, Wang Wenzhi, Wang Youxin, Wimo A, Yu Y, Zeng Q, Zhang W, Wei Wang*, Brayne C*, Moll van Charante EP*, **Richard E*** (* shared last author). Prevention of Dementia using Mobile Phone applications (PRODEMOS) – protocol for a randomized controlled trial. *BMJ Open* 2021;11(6):e049762
77. **Richard E**, den Brok M, Van Gool WA. Bayes analysis supports null hypothesis of anti-amyloid immunotherapy in Alzheimer's disease. *Alz & Dem* 2021;17(6):1051-55
78. Hilkens N, Klijn CJM, **Richard E**. Association between blood pressure, blood pressure variability and the risk of post-stroke dementia. *J Hypertension* 202;39(9):1859-64
79. Den Brok M, van Dalen JW, Abdulrahman H, Moll van Charante EP, van Gool WA, **Richard E**. Blood pressure lowering and the risk of dementia – a network meta-analysis. *J AM Med Dir Ass* 2021;22(7):1386-95
80. Hafdi M, **Richard E**, Moll van Charante EP, van Gool WA. Practice variation in the use of diagnostic tests in dementia. *Ned Tijdschr Geneesk* 2021 (article in Dutch) – online first 25 Feb 2021
81. Tromp K, Smedinga M, **Richard E**, Bunnik E, Perry M, Schermer M. Considerations in early diagnosis and biomarker use – a qualitative research among GPs, geriatricians and neurologists. *J Alz Dis* 2021;79(2):917-27
82. Klijs B, Mitratza M, Krepelanová E, Harteloh P, Moll van Charante EP, **Richard E**, Nielen MMJ, Kunst AE. Estimating the lifetime prevalence of dementia using Dutch causes of death data individually linked with other nationwide healthcare registrations. *Int J Epid* 2021;50(3):809-16
83. van Dalen JW, Mutsaerts HJ, Petr J, Moll van Charante EP, McIntosh BJ, van Gool WA, Nederveen A, **Richard E**. Antihypertensive drug use, not blood pressure, is associated with lower cerebral blood flow in older people with hypertension: longitudinal changes in cerebral blood flow in the prevention of dementia by intensive vascular care (preDIVA) MRI study. *JCBFM* 2021;41(7):1756-66

84. Uleman JF, Melis RJF, Quax R, van der Zee EA, Thijssen D, Dresler M, van de Rest O, van der Velpen IF, Adams HHH, Schmand B, de Kok IMCM, de Bresser J, **Richard E**, Verbeek M, Hoekstra AG, Rouwette EAJA, Olde Rikkert MGM. Mapping the Multicausality of Alzheimer's Disease through Group Model Building. *Geroscience* 2021;43(2):829-43
85. Smedinga M, Darweesh S, Schermer MH, Bloem B, Post B, **Richard E**. Towards early disease modification of Parkinson's disease – lessons learned from the Alzheimer field. *J Neurol* 2021;268(2):724-33
86. Smedinga M, **Richard E**, Schermer M, Bunnik E. The framing of Alzheimer's disease: differences between scientific and lay literature and their ethical implications. *Gerontologist* 2021;61(5):746-55
87. Van Dalen JW, Marcum Z, Crane P, Moll van Charante EP, Larson E, **Richard E**. Angiotensin-II stimulating antihypertensives are associated with lower incident dementia rates in community-dwelling older people: a longitudinal cohort study. *Neurology* 2021;96(1):e67-e80
88. Coley NC*, Hoevenaar-Blom MH*, van Dalen JW, Moll van Charante EP, Kivipelto M, Soininen H, Andrieu S#, **Richard E**#. Dementia risk scores as surrogate outcomes for lifestyle-based multidomain prevention trials – rationale, preliminary evidence and challenges . *Alz & Dem* 2020 16(12):1674-1685
89. Akenine U, Barbera M, Beishuizen C, Fallahpour M, Guillemont J, Rosenberg A, Coley N, Mangialasche F, Salo L, Pols J, Savy S, Andrieu A, **Richard E**, Soininen H, Moll van Charante EP, Kivipelto M. Prevention of cardiovascular disease and dementia using eHealth: a qualitative study of attitudes of at-risk older adults in a European context. *BMJ Open* 2020;10:e037050
90. Mutsaerts HJMM, Petr J, Groot P, Vandemaele P, Ingala S, Robertson AD, Václavů L, Groote I, Kuijf H, Zelaya F, O'Daly O, Hilal S, Wink AM, Kant I, Caan MWA, Morgan C, de Bresser J, Lysvik E, Schranter A, Bjørnebekk A, Clement P, Shirzadi Z, Kuijper JPA, Wottschel V, Anazodo UC, Pajkrt D, **Richard E**, Bokkers RPH, Reneman L, Masellis M, Günther M, MacIntosh BJ, Achten E, Chappell MA, van Osch MJP, Golay X, Thomas DL, De Vita E, Bjørnerud A, Nederveen A, Hendrikse J, Asllani I, Barkhof F. Explore ASL: a robust image processing workflow for single- and multi-centre ASL perfusion MRI studies. *Neuroimage* 2020 Jun 8;219:117031
91. Van Wanrooij L, Hoevenaar-Blom M, Coley N, Ngandu T, Meiller Y, Guillemont J, Rosenberg A, Beishuizen CB, Moll van Charante EP, Soininen H, Brayne C, Andrieu SA, Kivipelto M, **Richard E**. Pooling individual participant data from randomized controlled trials: exploring potential loss of information. *PLoS One* 2020;15(5):e0232790
92. **Richard E**, van Dalen JW, Moll van Charante EP. Genetic risk, lifestyle and the risk of dementia. *Ned Tijdschr Geneesk* 2020 Mar 19;164:D4864 (article in Dutch)

93. Brayne C, Barnes LE, Breteler M, Brooks RL, Dufouil C, Fox C, Fratiglioni L, Ikram MA, Kenny RA, Kivipelto M, Lobo A, Musicco M, Qiu C, **Richard E**, Riedel-Heller S, Ritchie C, Skoog I, Stephan B, Venneri A, Matthews FE. Dementia research fit for the planet: reflections on population studies of dementia for researchers and policy makers alike. *Neuroepidemiology* 2020 – online first 4 February
94. Van Bussel E, Hoevenaar-Blom MH, ...van Gool WA, **Richard E**, Moll van Charante EP. Predictive value in older people of traditional risk factors for cardiovascular disease – a systematic review. *Prev Med* 2020. Accepted for publication.
95. Peters R, Yasar S, Anderson CS, Andrews S, Antikainen R, Arima H, Beckett N, Beer JC, Bertens AS, Booth A, van Boxtel M, Brayne C, Brodaty H, Carlson MC, Chalmers J, Corrada M, DeKosky S, Derby C, Dixon RA, Forette F, Ganguli M, van Gool WA, Guaita A, Hever AM, Hogan DB, Jagger C, Katz M, Kawas C, Kehoe PG, Keinanen-Kiukaanniemi S, Kenny RA, Köhler S, Kunutsor SK, Laukkanen J, Maxwell C, McFall GP, van Middelaar T, Moll van Charante EP, Ng TP, Peters J, Rawtaer I, **Richard E**, Rockwood K, Rydén L, Sachdev PS, Skoog I, Skoog J, Staessen JA, Stephan BCM, Sebert S, Thijs L, Trompet S, Tully PJ, Tzourio C, Vaccaro R, Vaaramo E, Walsh E, Warwick J, Anstey KJ. *Neurology*. 2020 Jan 21;94(3):e267-e281.
96. Milne R, **Richard E**, Larson E, Brayne C. Innovation should support societal responsibility for health. *BMJ Opinion section*, online 30 Dec 2019
97. Lee C,**Richard E**..... Body weight, weight change and risk of dementia: a meta-analysis of 2,790,753 and 57,301 cases of dementia. *Obesity Reviews* 2020 – accepted for publication
98. Moll van Charante EP, **Richard E**. Practice variation in memory clinics – is this a problem? *Ned Tijdschr Geneesk* 2019 (Dutch)
99. **Richard E***, Moll van Charante EP*, Hoevenaar-Blom M, Coley, N, Barbera M, van der Groep B, Meiller Y, mangialasche F, Beihuizen C, Jongstra S, van Middelaar T, van Wanrooij L, Ngandu T, Guillemont J, Andrieu SA, Brayne C, Kivipelto M, Soininen H, van Gool WA. Healthy Ageing Through Internet Counselling in the Elderly (HATICE) – an international randomized controlled clinical trial. *The Lancet Digital Health* 2019;1(8):e424-34
100. Van Bussel E, Reurich AJ, Pols J, **Richard E**, van Gool WA, Ligtharts SA, Moll van Charante EP. Hypertension management: experiences, wishes and concerns among older people – a qualitative study. *BMJ Open* 2019Aug 18;9(8) e030742
101. Eggink E, Moll van Charante EP, van Gool WA, **Richard E**. Prevention of dementia from a population perspective. *J Clin Med* 2019;8:834
102. Brayne C & **Richard E**. prevention of cognitive decline – a goal in sight?. *J Alz Dis* 2019;70(S1):S11-S14
103. Van Bussel, **Richard E**, Busschers W, Steyerberg E, van Gool WA, Moll van Charante EP, Hoevenaar-Blom MP. A cardiovascular risk prediction model for

older people - development and validation. *Journal of Clinical Hypertension* 2019;21(8):1145-52

104. Hafdi M, Beishuizen CB, Hoevenaar-Blom M, Moll van Charante EP, **Richard E**, van Gool WA. Association of benzodiazepine and anticholinergic drug usage with incident dementia. *JAMDA* 2019; 9 July online first
105. Van Middelaar T, **Richard E**, van Gool WA, Moll van Charante EP, van Dalen JW. Visit to visit blood pressure variability and the progression of white matter hyperintensities. *JAMDA* 2019;20(9):11175-77
106. Coley N, Ngandu N, Lehtisalo J, Soininen H, Vellas B, **Richard E**, Kivipelto M*, Andrieu S* (shared last author). Adherence to multidomain interventions for dementia prevention: data from the FINGER and MAPT trials. *Alz & Dem* 2019. *Accepted for publication*
107. Beishuizen CRL, Akenine U, Barbera M, Rosenberg A, Fallahpour M, **Richard E**, Soininen H, Mangialasche F, Kivipelto M, Pols AJ and Moll van Charante EP. Integragating nurses' experiences with supporting behaviour change for cardiovascular prevention into a self-management internet platform in Finland and the Netherlands. *BMJ Open* 2019;9:e023480
108. Van Wanrooij L, **Richard E**, Jongsta SJ, van Gool WA, Moll van Charante EP. Predictive value of simple memory testing in a primary care setting. *Ann Fam Med* 2019;17(5):412-18
109. Van Wanrooij L, Borsboom D, Moll van Charante EP, **Richard E**, van Gool WA. Depressive symptom clusters and the risk of dementia – a network approach. *Int Psychogeriatrics* 2019. *Online first*.
110. Van Dalen JW, Moll van Charante EP, van Gool WA, **Richard E**. Discontinuation of antihypertensive medication, cognitive complaints and incident dementia. *JAMDA* 2019;20(9):1091-97
111. McCleery, Flicker L, **Richard E**, Quinn T. The National Institute of Ageing and Alzheimer's Association Research Framework – a commentary from the Cochrane Dementia and Cognitive Improvement Group. *Alz & Dem* 2019;15:179-81
112. Schermer M, **Richard E**. On the reconceptualization of Alzheimer's Disease. *Bioethics* 2019;33:138-45
113. Coley N, Rosenberg A, van Middelaar T, Soulier A, Barbera M, Guillemont J, Steensma J, Igier V, Eskelinen M, Soininen H, Moll van Charante EP, **Richard E**, Kivipelto M, Andrieu S, for the MIND-AD and HATICE groups. Older adults' reasons for participating in a multinational eHealth prevention trial: a cross-country comparison using mixed methods (ACCEPT-HATICE) – *JAMDA online first* 2018 Dec 9
114. Norrving B, Barrick J, Davalos A, Dichgans M, Cordonnier C, Farrington J, Guekht A, Kutluk K, Mikulik R, Wardlaw J, **Richard E**, Nabavi D, Molina C, Bath P, Rudd A, Drummond A, Planas A, Caso V on behalf of the *Action Plan for Stroke in Europe working group*. Action plan for stroke in Europe 2018-

115. Chai Y, Chen J, Galarza C, Sluman MA, Xu B, Vu CQ, **Richard E**, Mulder B, Tamrazi B, Lepore N, Mutsaerts HJMM, Wood JC. Cerebral blood flow and predictors of white matter lesions in adults with tetralogy of Fallot. *Proc IEEE Int Symp Biomed Imaging* 2018;Apr:1309-12
116. McCleery, Flicker L, **Richard E**, Quinn T. The National Institute of Ageing and Alzheimer's Association Research Framework – a commentary from the Cochrane Dementia and Cognitive Improvement Group. *Age & Ageing* 2018;Oct 17 epub ahead of print
117. Smedinga M, Tromp K, Schermer M, **Richard E**. Ethical arguments concerning the use of Alzheimer's Disease biomarkers in individuals with no or mild cognitive impairment – a systematic review and framework for discussion *J Alz Dis* 2018;66:1309-1322
118. Bunnik E, **Richard E**, Milne R, Schermer M. On the personal utility of Alzheimer's disease-related biomarker testing in the research context. *J Med Ethics* 2018;44(12):830-34
119. Van Dalen JW, Moll van Charante EP, **Richard E**, van Gool WA. Antihypertensive drugs, incident dementia and the competing risk of death. *JAMDA* 2018;Nov 19(11):1026-27
120. Zonneveld T, **Richard E**, Vergouwen MDI, Nederkoorn PJ, de Haan R, Roos YB, Kruijff ND. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. *Cochrane database of Syst reviews* 2018;7:CD007858
121. Van Dalen JW, Moll van Charante EP, Brayne C, van Gool WA, **Richard E**. Apathy and the risk of dementia – a systematic review and meta-analysis. *JAMA Psychiatry* 2018;75(10):1012-21
122. Van Middelaar T, Hoevenaar-Blom MP, Moll van Charante EP, van Gool WA, van Dalen JW, Deckers K, Koehler S, **Richard E**. Modifiable dementia risk score to study heterogeneity in treatment effect of a dementia prevention trial: a post hoc analysis in the preDIVA trial using the LIBRA index. *Alz Res Ther* 2018;10(1):62
123. Van Middelaar T, van Vught L, van Gool WA, moll van Charante EP, **Richard E**. The effect of blood pressure reduction on the incidence of dementia – a meta-analysis of randomized controlled trials. *J Hypertension* 2018;36(9):1780-89
124. Van Bussel E, hoevenaar-Blom MH, van Gool WA, **Richard E**, Moll van Charante EP. The effect of nurse-led intensive vascular care on cardiovascular disease risk in older people – a cluster-randomized controlled trial. *Am J Prev Med* 2018;55(3):368-75
125. Van Middelaar T, Argilander T, Schreuder F, **Richard E**, Klijn K. The effect of antihypertensive medication on cerebral small vessel disease: a systematic

review and meta-analysis. *Stroke* 2018 Jun; 49(6):1531-33

126. Van Middelaar T, Ivens S, van Peet P, **Richard E**, Pols J, Moll van Charante EP. (de)prescribing antihypertensive medication in older patients by general practitioners: a qualitative study. *BMJ Open* 2018;Apr 20;8(4):e020871
127. Jongstra SJ, van Gool WA, Eurelings LS, van Dalen JW, Moll van Charante EP, **Richard E**, Ligthart SA. The predictive value of MMSE decline for the development of dementia in a population-based setting. *Annals of Family Medicine* 2018;16(3):206-210
128. Eurelings LS, van Dalen JW, Moll van Charante EP, Buschers W, **Richard E**, van Gool WA. Apathy and depressive symptoms in older people and incident myocardial infarction, stroke, and mortality: a systematic review and meta-analysis of individual participant data. *J Clin Epidemiology* 2018 Apr 4;10:363-379
129. Ten Harmsen B, van Rumund A, Aerts M, Bergkamp M, Esselink RAJ, **Richard E**, F.J.A. Meijer, Bloem BR, van Wamelen DJ. Clinical correlates of cerebral white matter abnormalities in patients with Parkinson's disease. *Parkinsonism and related disorders* 2018:Apr;49:28-33
130. Barbera M, Mangialasche F, Jongstra S, Guillemont J, Ngandu T, Beishuizen C, Coley N, Brayne C, Andrieu S, **Richard E**, Soininen H, and Kivipelto M. Designing an internet-based multidomain intervention supporting vascular health of older Europeans: The HATICE trial. *J Alz Dis* 2018; 62(2):649-663

131. Milne R, Bunnik E, Diaz A, **Richard E**, Badger S, Gove D, Georges J, Faurina K, Molinuevo J, Wells K, Ritchie C, Brayne C. Perspectives on communicating biomarker-based assessments of Alzheimer's disease to cognitively healthy individuals. *J Alz Dis* 2018; 62(2):487-498

132. Van Middelaar T, van Dalen JW, van Gool WA, van den Born BJ, van Vught L, Moll van Charante EP, **Richard E**. Blood pressure variability and the risk of dementia. *J Alz Dis* 2018;62(2):727-735
133. van Middelaar T, Beishuizen CB, ,**Richard E**, Moll van Charante EP. Engaging older people in an internet platform for cardiovascular self-management: a qualitative evaluation. *BMJ Open* 2018;Jan 21;8(1):e019683
134. Van Dalen JW, van Wanrooij L, Moll van Charante EP, **Richard E**, van Gool WA. Apathy is associated with incident dementia in community-dwelling older people. *Neurology* 2018 Jan 2;90(1):e82-e89
135. Van Middelaar T, van Vught LA, Moll van Charante EP, Eurelings LSM, Ligthart SA, van Dalen JW, van den Born BJH, **Richard E**, van Gool WA. Lower dementia risk with different classes of antihypertensive medication

in older patients. *J Hypertension* 2017;35(10):2095-2101

136. Van Rooij FG, Plaizier NO, Vermeer SE, Góraj BM, Koudstaal PJ, **Richard E**, de Leeuw FE, Kessels RPC, van Dijk EJ. Subjective cognitive impairment, depressive symptoms, and fatigue after a TIA or transient neurological attack: a prospective study. *Behavioural Neurology* 2017:5181024
137. Van Rooij FG, Plaizier NO, Vermeer SE, Gorajs BM, Koudstaal PJ, **Richard E**, de Leeuw FE, Kessles RPC, van Dijk EJ. Executive function declines in the first six months after a TIA or transient neurological attack. *Stroke* 2017 Dec;48(12):3323-3328
138. **Richard E**, Moll van Charante EP. Diagnostiek bij geheugenklachten – bij wie, wat en wanneer. *Ned Tijdschr Geneesk* 2017;161(0):D2120 (Dutch)
139. Hoevenaar-Blom MH, Guillemont J, Hgandu T, Beishuizen C, Coley N, Moll van Charante EP, Andrieu SA, Kivipelto M, Soininen H, Brayne C, Meiller Y, **Richard E**. Improving data sharing in research with context-free encoded missing data. *PLoS One* 2017 Sep 12;12(9):e0182362
140. Van Dalen JW, Nederveen A, Caan M, Majoie CB, van Gool WA **Richard E**. The effect of long-term vascular care on progression of cerebrovascular lesions – the MRI sub study of the preDIVA randomized controlled trial. *Stroke* 2017 Jul;48(7):1842-1848
141. Van Middelaar T, van Vught L, Moll van Charante EP, Ligthart SA, van Dalen JW, Eurelings LS, **Richard E**, van Gool WA. Calcium antagonist treatment and the risk of dementia. *J Hypertension* 2017 Oct;35(10):2095-2101
142. Jongstra S, Wijsman L, Cachucho R, Hoevenaar-Blom MP, Mooijaart SP, **Richard E**. Cognitive Testing Using a Smartphone Application; the iVitality Proof of Principle Study. *JMIR mHealth uHealth* 2017; May 25;5(5):e68
143. Sluman MA, **Richard E**, van Wanrooij L, van Dalen JW, Groenink M, Caan MWA, Mutsaerts HJ, Majoie CB, Schmand B, Bouma B, Mulder B. Structural cerebral damage and cognition in adults with Tetralogy of Fallot. *Circulation* 2017; 135(19):1873-1875
144. Bedussi B, Naessens D, de Vos J, Olde Engberink R, Titze JM, Wilhelmus M, **Richard E**, ten Hove M, van Bavel E, Bakker NTP. Enhanced interstitial fluid drainage in the hippocampus of spontaneously hypertensive rats. *Sci Reports* 2017; 7(1):744
145. Su T, Mutsaerts HJ, Caan MW, Wit FW, Schouten J, Geurtsen GJ, Sharp DJ, Prins M, **Richard E**, Portegies P, Reiss P, Majoie CB; AGEHIV Cohort Study. Cerebral Blood Flow and cognitive function in HIV-Infected Men With Sustained Suppressed Viremia on Combination Antiretroviral Therapy. *AIDS* 2017 Mar 27;31(6):847-856.
146. Beishuizen C, Coley N, Moll van Charante EP, van Gool WA, **Richard E**, Andrieu SA. Determinants of dropout and non-adherence in a dementia prevention randomized controlled trial – the PreDIVA trial. *J Am Geriatr Soc* 2017; Jul;65(7):1505-1513

147. Mijajlovic MD; Pavlovic A; Brainin M; Heiss WD; Quinn TJ; Hansen HI; Hermann DM; Assayag EB; **Richard E**; Thiel A; Kliper E; Shin Y; Kim Y; Choi SH; Jung S; Lee YB; Sinanovic O; Levine DA; Schlesinger I; Mead G; Milosevic V; Leys D; Hagberg G; Ursin MH; Teuschl Y; Prokopenko S; Mozheyko E; Bezdenezhnykh A; Matz K; Aleksic V; Muresanu DF; Korczyn AD; Bornstein N. Consensus statement: Post-stroke cognitive impairment-dementia. *BMC Medicine* 2017 Jan 18;15(1):11
148. Moll van Charante EP*, **Richard E***, (equal contribution), Eurelings LS, van Dalen JW, Ligthart SA, Hoevenaar MH, Vermeulen M, van Gool WA. Preventie van dementie door intensieve vaatzorg – een cluster-gerandomiseerd onderzoek. *NTvG* 2017;161(0):D1184 (Dutch)
149. Van Bussel, **Richard E**, Matthews F, Brayne C, van Gool WA, Moll van Charante EP. Incidence of dementia in the Netherlands over the last three decades. *PLoS Med* 2017; Mar 7;14(3):e1002235
150. Jongstra S, Beishuizen C, Andrieu S, Barbera M, van Dorp M, van de Groep B, Guillemont J, Mangialasche F, van Middelaar T, Moll van Charante EP, Soininen H, Kivipelto M, **Richard E**. Development and pilot study of a multicomponent interactive internet platform for older people – the Healthy Ageing Through Internet Counselling in the Elderly study. *Telemedicine and e-Health* 2017; 23(2):96-104
151. Milne R, Bunnik E, Tromp K, Badger S, Brayne C, Schermer M, **Richard E**. Ethical issues in the development of clinical trial platforms for Alzheimer's disease: lessons from the European Prevention of Alzheimer's Dementia (EPAD) project. *J Prev Alz Dis.* 2017, Feb 22 (online first)
152. HJMM Mutsaerts, J Petr, L Vaclavu, JW van Dalen, AD Robertson, MW Caan, M Masellis, AJ Nederveen, **E Richard**, BJ MacIntosh. The spatial coefficient of variance (spatial CoV) of an arterial spin labeling image. *JCBFM* 2017; Sep;37(9):3184-3192
153. Bemelmans SJ, Tromp K, Bunnik E, Milne R, Badger S, Schermer M, **Richard E**. Psychological, behavioural and social consequences of disclosure of risk for Alzheimer's Disease – a systematic review. *Alz Res Ther* 2016 Nov 10;8(1):46
154. Van Dalen JW, Caan M, van Gool WA, **Richard E**. Disruption of the cholinergic projections is associated with clinical symptoms of the cholinergic deficiency syndrome in dementia. *Brain Imaging Behaviour* 2016, Oct 27.
155. Jongstra S, Harrison J, Noel-Storr A, Quinn T, **Richard E**. antihypertensive withdrawal to prevent cognitive impairment. *Cochrane database of systematic reviews* 2016 Nov 1;11:CD011971. Review
156. Beishuizen C, van Gool WA, Busschers W, Peters RGJ, Moll van Charante EP, **Richard E**. Internetinterventies voor cardiovasculaire risicofactoren bij mensen van middelbare leeftijd en ouder: een systematische review en meta-analyse. *NTvG* 2016; 2016;160(0):D581 (in Dutch)
157. **Richard E***, Moll van Charante EP* (equal contribution), Eurelings LS, van

Dalen JW, Ligthart SA, Hoevenaar-Blom MH, Vermeulen M, van Gool WA. Prevention of Dementia by Intensive Vascular care – the preDIVA trial. *Lancet* 2016 Aug 20;388(10046):797-805

158. I.W.M. van Uden, H.M. van der Holst, E.M.C. van Leijssen, A.M. Tuladhar, A.G.W. van Norden, K.F. de Laat, J.A.H.R. Claassen, E.J. van Dijk, R.P.C. Kessels, **E. Richard**, I. Tendolkar, F-E de Leeuw. Late onset depressive symptoms increase the risk of dementia in small vessel disease. *Neurology* 2016; 87(11):1102-9
159. Su T, Wit FWNM, Caan MWA, Schouten J, Stolte IG, Geurtsen GJ, Cole JH, Sharp DJ, **Richard E**, Reneman L, Portegies P, Reiss P, Majoie CB. White Matter Hyperintensities in Relation to Cognition in HIV-infected Men with Sustained Suppressed Viral Load on cART. *AIDS* 2016; 30(15):2329-39
160. Wijsman L, **Richard E**, Jongstra S, de Craen A, Mooijaart S. Evaluation of the Use of Home Blood Pressure Measurement Using Mobile Phone-Assisted Technology: The iVitality Proof-of-Principle Study. *J Med Int Res – mHealth and uHealth* 2016;4(2):e67
161. Van Dalen JW, Mutsaerts HJ, Steenwijk M, Vrenken H, van Gool WA, Nederveen A, **Richard E**. Chronic hypoperfusion is associated with cerebral white matter hyperintensities. *Am J Neuroradiol* 2016. June 9. Online first
162. Van Middelaar T, **Richard E**, Visser M, van de Munckhof P, Nederkoorn PJ. Kwaliteit van leven na hemicraniectomie voor ruimte-innemend herseninfarct. *Tijdschr Neurol Neuruchir* 2016;117(2):63-66 (Dutch)
163. **Richard E**, Jongstra S, Soininen H, Brayne C, Moll van Charante EP, Meiller Y, van der Groep A, Beishuizen CR, Mangialasche F, Barbera M, Ngandu T, Coley N, Guillemont J, Savy S, Dijkgraaf MG, Peters RJ, van Gool WA, Kivipelto M, Andrieu S. The Healthy Aging Through Internet Counseling in the Elderly (HATICE) trial. *BMJ Open* 2016;6:e010806
164. Beishuizen C, Stephan B, Moll van Charante EP, Brayne C, Kivipelto M, Andrieu S, Soininen H, van Gool WA, **Richard E**. Effect of cardiovascular risk management using internet applications.- syst review and meta-analysis. *J Med Int Res* 2016;18(3):e55
165. Van Rooij FG, Kessels RPC, **Richard E**, de Leeuw FE, van Dijk EJ. Cognitive impairment in transient ischaemic attack patients: a systematic review and meta-analysis. *Cerebrovascular Diseases* 2016;18(42):1-9
166. Van Leeuwen N, Lingsma H, de Craen A, Nieboer D, **Richard E**, Steyerberg E. Regression discontinuity (RD) design: simulation and application in two cardiovascular trials with continuous outcomes *Epidemiology* 2016; 27(4):503-11
167. Van Uden I, van der Holst MP, Schaapsmeeders P, van Norden AGW, de Laat KF, Norris DG, Claassen JAHR, van Dijk EJ, **Richard E**, Kessles RPC, de Leeuw FE. Microstructural integrity and cognitive decline after 5 years; the RUN DMC study. *BBA Clinical* 2015;26:108-114

168. Eurelings LS, Jaccard J, Moll van Charante EP, Ligthart SA, van Gool WA, **Richard E**. Apathy, depression and incident cardiovascular disease – mediation by cardiovascular risk factors. *Int Psychogeriatr* 2015;Nov 6:1-11
169. Frank G van Rooij, Sarah E Vermeer, Bozena M Góraj, Peter J Koudstaal, **Edo Richard**, Frank-Erik de Leeuw, Ewoud J van Dijk. Diffusion-weighted imaging in transient neurological attacks. *Annals of Neurology* 2015; Oct 8
170. Mutsaerts HJ, van Dalen JW, Heijtel DFR, Majoie CB, **Richard E**, Nederveen AJ. Cerebral perfusion measurements in the elderly using arterial spin labelling. *PLoS One* 2015;10(8):e0133717
171. Middelaar T, **Richard E**, van der Worp B, Stam J, vd Munckhof P, Nieuwkerk P, Nederkoorn PJ. Quality of life in patients and caregivers after hemispherectomy for a cerebral infarct. *BMC Neurology* 2015;15(1):156
172. Van Gool W.A., **Richard E**. The limited role of neuroimaging in predicting and diagnosing dementia. *BMJ* 2015;350:h2994
173. Den Brok M, van Dalen JW, Moll van Charante EP, van Gool WA, de Bie RM, **Richard E**. Apathy in Parkinson's Disease – a systematic review and meta-analysis. *Mov Disord.* 2015 May;30(6):759-69
174. Pauline Aalten, Inez HGB Ramakers, Geert Jan Biessels, Peter Paul de Deyn, Marcel GM OldeRikkert, Ania M Oleksik, **Edo Richard**, Liek L Smits, John C van Swieten, Frans RJ Verhey, Wiesje M van der Flier. The Dutch String of Pearls institute – Neurodegenerative diseases; methods, design and baseline results. *BMC Neurol.* 2014 Dec 31;14(1):1060
175. Eurelings LS, **Richard E**, Ligthart SA, van Gool WA, Moll van Charante EP. Low-grade inflammation differentiates between symptoms of apathy and depression in community-dwelling older people. *Int Psychogeriatr.* 2015 Apr;27(4):639-47
176. Van Dalen JW, Scuric E, Caan M, Nederveen A, van Veluw S, Biessels GJ, van Gool WA, **Richard E**. Cortical microinfarcts detected in vivo on 3 Tesla MRI – clinical and radiological correlates. *Stroke.* 2015 Jan;46(1):255-7
177. Research focus on post-stroke cognitive deterioration: an update and recommendations. Brainin M, Tuomilehto J, Heiss WD, Bornstein N, Bath PMW, Teuschl Y, **Richard E**, Guekht A, Quinn T, for the Post Stroke Cognition Study Group. *Eur J Neurol.* 2015 Feb;22(2):229-38
178. **Richard E**, Brayne C. Dementia prevention strategies – Beyond the randomized controlled trial? *J Prev Alz Dis* 2014;1:62-4
179. Ligthart SA, van den Eerenbeemt KDM, Pols J, van Bussel E, **Richard E**, Moll van Charante EP. What makes cardiovascular consultations work? A qualitative inquiry into elderly participants' perspectives. *Br J Gen Pract.* 2015 Jan;65(630):e41-8
180. Rasing I, van der Salm S, **Richard E**, Kruyt ND. Reversible symptomatic communicating hydrocephalus in two patients with a vestibular schwannoma. *Tijdschr Neurol Neurochir* 2015;116:47-50 (Dutch)

181. Middelaar, T, Nederkoorn PJ, van der Worp B, Stam J, **Richard E**. Quality of life after hemicraniectomy for malignant cerebral infarct - a systematic review. *Int J Stroke*. 2015 Feb;10(2):170-6
182. **Richard E**, Khachaturian A. Multi-domain prevention for a multifactorial disease. *J Prev Alz Dis* 2014;1:4-5
183. Noel-Storr A, Mc Leery J, **Richard E**, ,McShane R. Harmonisation of reporting standards for studies of diagnostic test accuracy in dementia: the STARDdem (STAndards for the Reporting of Diagnostic accuracy studies-dementia) initiative. *Neurology* 2014;83:364-73
184. **Richard E** and Brayne C. Mild cognitive impairment – not always what it seems. *Nature Rev Neurology* 2014;10:130-31
185. Schmand B, Rienstra A, Tamminga H, **Richard E**, van Gool WA, Caan M, Majoie, CB. Responsiveness of MRI and neuropsychological assessment in memory clinic patients. *J Alz Dis* 2014;40:409-18
186. Solomon A, Mangialasche F, **Richard E**, Andrieu S, Bennett DA, Breteler M, Fratiglioni L, Hooshmand B, Khachaturian AS, Skoog I, Schneider L, Kivipelto M. Advances in the prevention of Alzheimer's disease. *J Int Med* 2014;275:229-50
187. Eurelings LS, Ligthart SA, Moll van Charante EP, van Gool WA, **Richard E**. Apathy and the risk of incident cardiovascular disease. *Int J Ger Psychiatr* 2014;29:454-63
188. Mutsaerts HJ, **Richard E**, Heijtel DFR, Majoie CBLM, van Osch MJP, Nederveen A. White matter perfusion measurement based on arterial spin labelling in cognitive impairment and dementia. *Neuroimage clinical* 2013;4:139-44
189. Steenwijk, MD, Pouwels PJW, Daams M, van Dalen JW, Caan M, **Richard E**, Barkhof F, Vrenken H. Accurate white matter lesion segmentation by *k* nearest neighbor classification with tissue type priors (*k*NN-TTP). *Neuroimage clinical* 2013; 3:462-69
190. **Richard E**, Schmand B, Eikelenboom P, van Gool WA. MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study *BMJ open* 2013;3:e002541
191. van Dalen JW, Moll van Charante EP, Nederkoorn PJ, van Gool WA, **Richard E**. Post-stroke apathy. *Stroke* 2013;44(3):851-60
192. **Richard E**, Reitz C, L.H. Honig,N. Schupf, M.X. Tang, J.J. Manly, R. Mayeux, D.P. Devanand, Luchsinger JA. Late life depression, mild cognitive impairment and dementia. *JAMA Neurol* 2013;70(3):374-82
193. **Richard E**, Schmand B, Eikelenboom P, Westendorp RJ, Van Gool WA. The Alzheimer Myth and Biomarker Research in Dementia. *J Alz Dis* 2012.31

194. **Richard E**, Andrieu S, Solomon A, Ahtiluoto S, Moll van Charante EP, Coley N, Mangialasche F, Fratiglioni L, Stigsdotter-Neely A, Vellas B, van Gool WA, Kivipelto M. Methodological challenges in designing dementia prevention trials – The European Dementia Prevention Initiative. *J Neurol Sci* 2012;322:64-70
195. **Richard E**, Moll van Charante EP, van Gool WA. Vascular risk factors as treatment target to prevent cognitive decline. *J Alz Dis* 2012;32:733-40
196. Schoenmaker N, Germans M, Troost D, **Richard E**. A remarkable pattern of subcortical vessel wall enhancement in granulomatous angiitis of the central nervous system. *Journal of Rheumatology* 2012;39:2051-53
197. **Richard E**, Schmand B, Eikelenboom P, Yang SC, Ligthart SA, Moll van Charante EP, van Gool WA. Symptoms of apathy are associated with progression from MCI to Alzheimer's disease in non-depressed subjects. *Dement Ger Cogn Disord* 2012;33:204-209
198. Ligthart SA, **Richard E**, Fransen N, Eurelings LS, Beem L, Eikelenboom P, van Gool WA, Moll van Charante EP. Vascular factors are associated with apathy in community-dwelling elderly. *Archives of General Psychiatry* 2012;69:636-642
199. Ligthart SA, **Richard E**, Moll van Charante EP, Van Gool WA. Cardiovascular risk factors in community-dwelling elderly – opportunities for prevention. *Eur J Prev Cardiol* 2012;19:1365-72
200. Andrieu S, Aboderin I, Bayens JP, Beard J, Benetos A, Berrut G, Brainin M, Cha HB, Chen LK, Du P, Forette B, Forette F, Franco A, Fratiglioni L, Gillette-Guyonnet S, Gold G, Gomez F, Guimaraes R, Gustafson D, Khachaturian A, Luchsinger JA, Mangialasche F, Mathiex-Fortunet H, Michel JP, **Richard E**, Schneider LS, Solomon A, Vellas B. Health promotion program on the prevention of late onset dementia. *J Nutr, Health Aging* 2011;15:562-75
201. Wieske L, Vergouwen MD, Wijers D, Stam J, Smets EMA, **Richard E**. Limited benefit of diagnostic second opinions in a neurology department. *Ned Tijdschr Geneesk* 2011;155:A3542 (Dutch)
202. Wieske L, **Richard E**, Wijers D, Stam J, Smets EM, Vergouwen M. long-term effects of second opinions and tertiary referrals in neurology. *European Journal of Neurology* 2011;18:1310-16
203. **Richard E**, Van Gool WA. There are two types of disease. *BMJ* 2010;341:c6327 (letter)
204. **Richard E**, Carrano A, Hoozemans J., Van Horsen J, Van Haastert E, Eurelings LSM, Eikelenboom P, Van Gool WA, Rozemuller J.M. "Characteristics of Dyschoric Capillary Cerebral Amyloid Angiopathy". *Journal of Neuropathology and Experimental Neurology* 2010;69:1158-67
205. Thoonsen H, **Richard E**, Bentham P, Gray R, De Haan RJ, Van Gool WA, Nederkoorn PJ. Aspirin in Alzheimer's disease: Increased risk for intracerebral

haemorrhage – Cause for Concern? *Stroke* 2010;41:2690-92

206. **Richard E**, Van Gool WA, Hoozemans JJM, Van Haastert ES, Eikelenboom P, Rozemuller AJM, Van de Berg WDJ. Morphometric changes in the cortical microvascular network in Alzheimer's Disease. *J Alz Dis* 2010;22:811-818
207. **Richard E**, Ligthart SA, Moll van Charante EP, Van Gool WA. Vascular risk factors and dementia – towards prevention strategies. *Neth J Med* 2010;68:284-90
208. Wijers D, Wieske L, Vergouwen MD, **Richard E**, Stam J, Smets EM. Patient satisfaction in neurological second opinions and tertiary referrals. *J Neurol* 2010;257:1869-74
209. Ligthart SA, Moll van Charante EP, van Gool WA, **Richard E**. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia – a review. *Vascular Health and Risk Management* 2010;6:775-85
210. Eurelings LS, **Richard E**, Carrano A, Eikelenboom P, Van Gool WA, Rozemuller JM. Dyshoric capillary cerebral amyloid angiopathy mimicking Creutzfeldt-Jakob disease. *J Neurol Sci* 2010;295:131-134
211. **Richard E**, Ligthart SA, Moll van Charante EP, Van Gool WA. Methodological issues in a cluster-randomized trial to prevent dementia by intensive vascular care. *J Nutr Health Aging* 2010;14:315-17
212. Kloppenborg RP, **Richard E**, Sprengers M, Troost D, Nederkoorn PJ. Steroid responsive encephalopathy in cerebral amyloid angiopathy: a case report and review of evidence for immunosuppressive treatment. *J Neuroinflammation* 2010;7:18
213. **Richard E**, Gouw AA., Scheltens P, Van Gool WA. Effect of intensive vascular care on the progression of MRI abnormalities in Alzheimer patients with cerebrovascular lesions – The EVA-study. *Stroke* 2010;41:554-56
214. **Richard E**, Kuiper R, Dijkgraaf MGW, van Gool WA. Vascular Care in Alzheimer's disease patients with cerebrovascular lesions – a randomized clinical trial. *J Am Geriatr Soc.* 2009;57:797-805
215. **Richard E**, v.d. Heuvel E, Moll van Charante EP, Achthoven L, Vermeulen M, Bindels PJE, Van Gool WA. Prevention of dementia by intensive vascular care (preDIVA); a cluster randomized trial in progress. *Alz Dis Assoc Dis* 2009;23:198-204
216. **Richard E**, Nederkoorn PJ. Clinical applicability of the term 'transient neurological attack'. *Ned Tijdschr Geneesk* 2008;152:1086-1087 (article in Dutch)
217. Wieske L, Wijers D, **Richard E**, Vergouwen MD, Stam J. Second opinions and tertiary referrals in neurology: A prospective observational study. *J Neurol.* 2008;255:1743-1749.
218. **Richard E**, van Gool WA. No evidence for efficacy of cholinesterase inhibitors

in early stages of Alzheimer's Disease. *Tijdschr Neurol Neurochir* 2008;109:297-300 (article in Dutch)

178. van Weert JM, Hajenius PJ, **Richard E**, Wolf H, Bleeker OP. Late postpartum eclampsia. *Ned Tijdschr Geneesk* 2007; 151:414-18 (article in Dutch)
179. Lemstra AW, **Richard E**, van Gool WA. Cholinesterase inhibitors in dementia: yes, no, or maybe? *Age Ageing*. 2007;36:625-627
180. **Richard E**, van Gool WA. Cholinesterase inhibitors in dementia: the precarious balance between efficacy and safety. *Ned Tijdschr Geneesk* 2006; 150; 530-2. (article in Dutch)
181. **Richard E**, Walstra GJ, Van Campen J, Vissers E, Van Gool WA. Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy. *Ned Tijdschr Geneesk* 2002;146:24-27(article in Dutch)
223. **Richard E**, Lemstra AW, Walstra GJM, van Gool WA. Evaluation of the therapeutic effects in individual patients with Alzheimer disease. *Ned Tijdschr Geneesk* 2001;145:340-45 (article in Dutch)
224. Rogaeva EA, Fafel KC, Song YQ, Medeiros H, Sato C, Liang Y, **Richard E**, Rogaev EI, Frommelt P, Sadovnick AD, Meschino W, Rockwood K, Boss MA, Mayeux R, St George-Hyslop P. Screening for PS1 mutations in a referral-based series of AD cases. 21 Novel mutations. *Neurology* 2001;57:621-25
225. **Richard E**, Vreede WB, von Rosenstiel IA. A Family with Malaria: Family with malaria: from the asymptomatic to life-threatening. *Ned Tijdschr Geneesk* 2001;145:2361-2364. (article in Dutch)
226. Nicolaou M, Song YQ, Sato CA, Orlacchio A, Kawarai T, Medeiros H, Liang Y, Sorbi S, **Richard E**, Rogaev EI, Moliaka Y, Bruni AC, Jorge R, Percy M, Duara R, Farrer LA, St George-Hyslop P, Rogaeva EA. Mutations in the open reading frame of the β -site APP cleaving enzyme (BACE) locus are not a common cause of Alzheimer's disease. *Neurogenetics* 2001;3:203-206

Projects

Title: Prevention of dementia with angiotensin-II stimulating antihypertensive medication (PREDAM); Agency: Alzheimer Nederland; Role: (co-)PI; Dates: 2025-2033; Amount: **€ 325.000**; Goal: to perform a RCT comparing two AHM strategies with dementia or clinically relevant cognitive decline as primary outcome, in collaboration with Shantou University Medical College, China

Title: Stopping or continuing antiplatelet therapy in young stroke patients (STOP); Agency: ZonMW; Role: (co-)PI; Dates: 2024-2032; Amount: **€ 1.856.000**; Goal: to confirm non-inferiority of stopping antiplatelet therapy in patients with cryptogenic stroke at young age

Title: Biomarking The Brain; Agency: ZonMW; Role: (co-)PI; Dates: 2023-2027; Amount: **€ 750.000**; Goal: To reconstruct, evaluate and guide the ongoing biomarkerization of brain diseases and its implications for patients, healthcare and society

Title: Netherlands Dementia Prevention initiative (NDPI); Agency: ZonMW; Role: (co-)PI; Dates: dec 2022- dec2026; Amount: **€ 3.000.000**; Goal: to develop and test lifestyle interventions to reduce the risk of dementia in those with low SES and/or a migration background;

Title: Primary care diagnostics or diagnostics in a memory clinic in older persons with memory complaints – A long-term cost-effectiveness trial with non-inferiority design; Agency: ZonMW Doelmatigheid (effectiveness research); Role: (co-)PI; Dates: 2023-2027; Amount: **€ 594.000**; Goal: Investigate whether diagnostics for memory complaints in those over 70 without red flags in primary care is not inferior to memory clinic referral, with functioning after 30 months as primary outcome

Title: Hypertension and dementia _ From epidemiology via neuropathology to therapeutic interventions. Agency: ZonMW (Netherlands Organisation for Health Research) Role: PI (personal grant) Dates: 01/10/2018 – 30/09/2023 Amount: € 800.000 Goal: to better understand the complex relation between hypertension, antihypertensive medication use and dementia risk from a population perspective, to ultimately develop intervention studies using targeted and age-specific hypertension treatment to prevent dementia.

Title: Prevention of Dementia Using Mobile Phone Applications (PRODEMOS) Agency: European Commission (H2020) Role: PI and coordinator Dates: 01_01_2018 till 31_12_2022 Amount: € 2.999.097, of which € 770.375 for coordinator Goals: making prevention of dementia strategies using mobile health accessible to persons at high risk with low SES in Europe and in China Title: Early Diagnosis of Alzheimer's Disease: Conceptual considerations and ethical Guidance Agency: ZonMW Role: co-PI Dates: 01/06/2016 – 31/12/2017 Amount: € 100.000 Goals: To provide ethical guidance for early Alzheimer's Disease diagnosis in clinical practice

Title: Healthy Aging Through Internet Counselling in the Elderly (HATICE) Agency: European Commission, 7th Framework Program, project 305374_2 Role: Initiator, coordinator (one of two coordinators) and work package leader Dates: 01/01_2013 – 31/12/2017 Amount: € 5.824.000

for the whole project; € 1.900.000 for Coordinator Goals: Optimisation of management of elderly with multiple cardiovascular diseases or risk factors to prevent cognitive decline, dementia and cardiovascular disease Title: prevention of dementia by intensive vascular care (preDIVA); RCT in 3533 elderly; Completion expected in 2015 Role: co_PI (funding obtained by PI W.A. van Gool) Aim: investigate if 6_year intensive vascular care can prevent the onset of dementia.

Title: A New Perspective on Dementia: from risk factors to prevention Agency: Alzheimer's Association 'New Investigator research Grant' NIRG_10_173212 Role: PI Dates: 01/01/2011 – 01/01/2013 Amount: US\$ 80.000 Goals: Defining most relevant risk factors for dementia and designing new intervention trials to prevent dementia

Title: A New Perspective on Dementia: from vascular risk factors towards prevention Agency: Internationale Stichting Alzheimer Onderzoek (ISAO) #10507 Role: PI Dates: 01/01/2011_01/01/2014 Amount: € 100.000 Goals: to evaluate the effect of intensive vascular care on the progression of white matter lesions, infarcts and microbleeds in an elderly population

Title: Multimodal preventive trials for Alzheimer's disease: towards multinational strategies (MIND_AD) Agency: Joint Programming Neurodegenerative Diseases (JPND) of the European Union Role: WP leader (coordinator Miia Kivipelto, Karolinska Institutet) Dates: 2015_2017 Amount: € 244.000 Goals: develop guidelines and recommendations for dementia prevention studies

Title: Towards innovation of clinical trials in old age using modern technology and alternative methodology Agency: ZonMW Role: WP leader/partner; Coordinator and PI: Dr. S. Mooijaart, Institute for Evidence Based Medicine in the Elderly (IEMO) and LUMC Dates: 01/11/2012 – 31/10/2015 Amount: € 179.039 (of total grant amount of € 600.000) Goals: To perform a proof_of_principle study using an innovative e_health application on smart phones for blood pressure monitoring in children of patients with dementia

Title: Early Diagnosis of Alzheimer's Disease: Conceptual considerations and ethical Guidance Agency: ZonMW Role: co_PI Dates: 01/06/2016 – 31/12/2017 Amount: € 100.000 Goals: To provide ethical guidance for early Alzheimer's Disease diagnosis in clinical practice

Title: European Prevention of Alzheimer's Disease consortium (EPAD) Agency: Innovative Medicines Initiative of the European Union (IMI) Role: WP leader (coordinator C. Ritchie, Edinburgh, UK) Dates: 2015_2019 Amount: € 233.000 Goals: Ethical legal and social issues of phase 2 dementia prevention studies, in particular concerning risk disclosure based on biomarkers

Memberships

Founder of the European Dementia Prevention Initiative (EDPI; www.edpi.org). Investigator_initiated collaboration between research groups involved in large_scale dementia prevention RCTs. Memberships: _ European Stroke Organisation / World Stroke Organisation _ Dutch Neurological Society _ Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) Editorial appointments: 2014_ J Prevention of Alzheimer Disease _ editor 2013-2021 Cochrane Dementia Group for Diagnostic Test Accuracy studies_ editor 2011_2016 J Alzheimer's Disease – associate editor

Invited lectures (selection):

2025 CME conference specialists elderly care The Netherlands (Den Bosch) – diagnostics and treatment of Alzheimer's Disease ; 2024 European Stroke Organisation Conference (Basel) – Prevention of Dementia using mobile phone applications (PRODEMOS-**plenary**); 2024 European Stroke Organisation Conference (Basel) - Secondary prevention in the elderly – first do no harm; 2024 Dutch Ministry of Health care dementia conference – new drug developments in Alzheimer's Disease; 2024 Presymptomatic Alzheimer's Disease – a useful concept? Dutch Neurological society movement disorders working group – (**keynote**); 2023 High level international meeting of Dutch Ministry of Health (Defeating Dementia) – Prevention of Dementia (**Keynote**); 2023 European Stroke Organisation Congress – a-symptomatic small vessel disease on MRI – what do I tell my patients? (**invited**); 2023 CME South-western neurologists Netherlands – dementia ; **2023** Int Psychogeriatric Association (IPA) – webinar Novel drug treatments in Alzheimer's Disease; 2022 Alzheimer Europe – Individual dementia risk reduction – where to move next (invited – key note) 2022 Alzheimer's Disease International Conference – population_approaches to dementia prevention. (invited) 2021 European Stroke Organisation Science Workshop, München – prevention of dementia after stroke (invited, key_note) 2021 VasCog – prevention of dementia from a public health perspective (invited) 2021 Scottish National Dementia Consortium annual meeting (invited, plenary) 2021 AAIC satellite symp. (lifestyle interventions to prevent dementia (invited) 2021 CarVascGer congress (dutch): Prevention of dementia (Invited) 2020 Prevention Day – Prevention of Dementia (invited) 2020 Alzheimer Europe Conference (Virtual due to COVID_19) – Ethical issues in diagnosis disclosure (invited, plenary) 2020 International Psychogeriatric Association (Lisbon)_ Multidomain interventions to reduce the risk of dementia – clinical trials preparing for the future (invited) 2020 European Stroke Organisation Conference (Vienna) – Vascular risk factors in AD (invited) 2020 Netherlands Memory Clinic Network Conference – lifestyle and dementia (invited) 2020 Dutch Northern Neurological Society – Diagnostics in dementia (invited teaching lecture) 2019 Radboud Reflects – towards an earlier diagnosis of Alzheimer's Disease (invited) 2019 Clinical Commissioning Group Cambridge – dementia prevention from an individual perspective (invited) 2019 European Stroke Organisation Conference (Milan) – post_stroke cognitive impairment (invited) 2019 Neurologie Jaarcongres – developments in dementia (Dutch, invited) 2019 Netherlands Neurovascular working group (Dutch, invited) – apathy and depression after stroke 2018 European Parliament Lunch meeting (Brussels) – European Dementia Prevention Initiative (invited) 2018 European Stroke Organisation Conference (Gothenborg) – lifestyle interventions and the risk of dementia (invited) 2017 European Stroke Organisation Science meeting (Garmisch Partenkirchen) – multi_domain interventions to prevent dementia (invited, keynote) 2017 TN2 conference (Amsterdam) – prevention of dementia (invited) 2017 JPND workshop Public Health (Paris, Fr) – 21st Century Eurodem (Invited) 2017 Alzheimer's Association International Conference (London, UK) – Healthy Ageing Through Internet Counselling in the Elderly (invited) 2017 Dutch Society for Research on Ageing (DuSRA) – Healthy Ageing Through Internet Counselling in the Elderly (invited) 2017 European Stroke Organisation Conference (Prague) – lifestyle interventions to prevent cognitive decline (invited) 2017 Biemond course (Dutch Neurological Society annual CME) – early cognitive impairment (invited) 2017 Alzheimer's Research UK workshop – prevention of dementia: current status and future perspectives (invited) 2017 Netherlands Neurovascular Working Group – vascular risk management for the prevention of dementia (invited) 2016 Global Alzheimer Leadership Series (GoALS) on vascular contribution to Alzheimer's Disease – Prevention from a population perspective (invited) 2016 Ethical considerations for dementia prevention trials – symposium ErasmusMC. Before it is too late: Professional responsibilities in late_onset Alzheimer's research and pre_symptomatic prediction (invited) 2016 Apathy: epidemiology, risk factors, and neuroimaging – Boerhaave cursus, Leiden, Netherlands (invited) 2015 Alzheimer's Research UK, London. Barriers and solutions to dementia prevention. (invited) 2015 NIH_collaboratory Grand Round, Duke University, USA. preDIVA and HATICE (invited) 2013 G8 dementia summit, London, UK: Prevention of dementia from a public health perspective 2013 Dementia Update, Amsterdam, the Netherlands: The European Dementia Prevention Initiative 2012 Alzheimer's Association International Conference, Vancouver, Canada: Intensive Vascular Care in Dementia Prevention 2012 International Salzburg Conference on Neurorecovery, Salzburg, Austria: Prevention of cognitive decline by vascular risk modification 2012 Alzheimer's Disease International, London: Prevention of Dementia in European collaboration 2012 Endo_neuro_psycho meeting, Lunteren, NL: The metabolic syndrome and Alzheimer's Disease 2011 European Stroke Organisation Science Workshop, Garmisch Partenkirchen: Vascular risk factor modification to prevent dementia. 2011 Vascular Dementia, Riga: Prevention of dementia by intensive vascular care – is it feasible? 2010 Community_based dementia prevention strategies, Columbia University, NY: 'Prevention of dementia by intensive vascular care'. 2010 'Neurologie Jaarcongres 2010': 'Neurodegenerative diseases'.

Other Relevant Information

2022 Chair of Dutch Society of Neurology CME committee (Biemond committee) 2018_ Editor in Chief of Textbook of Neurology (in Dutch) 2013 _ Cochrane dementia and cognitive improvement group _ Senior Editor 2012_ Core_member working group of Cochrane initiative STARDdem: Adaptation of guidelines for reporting of diagnostic accuracy studies in dementia 2011 Workshop of the International Association of Gerontology and Geriatrics (IAGG) / World Health Organisation (WHO), Geneva: Health Promotion Program on Prevention of Late_onset Dementia; invited participant